Literature DB >> 9240690

Effects of glycosylation on the properties and functions of influenza virus hemagglutinin.

I T Schulze1.   

Abstract

The influenza virus A hemagglutinin (HA) is a trimeric glycoprotein that contains 3-9 N-linked glycosylation sequons per subunit, depending on the strain. The location of these sites is determined by the nucleotide sequence of the HA gene, and, since the viral genome is replicated by an error-prone RNA polymerase, mutations, which add or remove glycosylation sites, occur at a high frequency. Mutations that are not lethal to the virus add to the structural diversity of the virus population. Factors that determine the glycosylation of the HA are reviewed herein, as are the effects of host-specific glycosylation on receptor binding, fusion activity, and antigenic properties of the virus. Effects of host-specific glycosylation and selection on virulence and on vaccine efficacy and surveillance are discussed. In addition, inadequacies in our understanding of HA glycosylation and its effects on host range are emphasized.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9240690     DOI: 10.1086/514170

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  70 in total

1.  Diversifying evolution of highly pathogenic H5N1 avian influenza virus in Egypt from 2006 to 2011.

Authors:  E M Abdelwhab; Abdel-Satar Arafa; Jürgen Stech; Christian Grund; Olga Stech; Marcus Graeber-Gerberding; Martin Beer; Mohamed K Hassan; Mona M Aly; Timm C Harder; Hafez M Hafez
Journal:  Virus Genes       Date:  2012-06-05       Impact factor: 2.332

2.  Amino acid sequence analysis and identification of mutations under positive selection in hemagglutinin of 2009 influenza A (H1N1) isolates.

Authors:  Xiaofan Ding; Lifang Jiang; Changwen Ke; Zhan Yang; Chunliang Lei; Kaiyuan Cao; Jun Xu; Lin Xu; Xingfen Yang; Yonghui Zhang; Ping Huang; Weijun Huang; Xun Zhu; Zhenjian He; Liping Liu; Jun Li; Jie Yuan; Jueheng Wu; Xiaoping Tang; Mengfeng Li
Journal:  Virus Genes       Date:  2010-08-31       Impact factor: 2.332

3.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

4.  Characterization of the 1918 "Spanish" influenza virus neuraminidase gene.

Authors:  A H Reid; T G Fanning; T A Janczewski; J K Taubenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Molecular analysis of influenza A H1N1pdm09 virus circulating in Madhya Pradesh, India in the year 2017.

Authors:  Salonee Pandey; Mahima Sahu; Varsha Potdar; Pradip Barde
Journal:  Virusdisease       Date:  2018-07-16

6.  Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene.

Authors:  A H Reid; T G Fanning; J V Hultin; J K Taubenberger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin.

Authors:  Yasuhiro Abe; Emi Takashita; Kanetsu Sugawara; Yoko Matsuzaki; Yasushi Muraki; Seiji Hongo
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Influenza B virus victoria group with a new glycosylation site was epidemic in Japan in the 2002-2003 season.

Authors:  Naoko Nakagawa; Ritsuko Kubota; Akiko Maeda; Yoshinobu Okuno
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

9.  Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin.

Authors:  Joshua L Cherry; David J Lipman; Anastasia Nikolskaya; Yuri I Wolf
Journal:  PLoS Curr       Date:  2009-08-18

10.  An inactivated vaccine to control the current H9N2 low pathogenic avian influenza in Korea.

Authors:  Jun Gu Choi; Youn Jeong Lee; Yong Joo Kim; Eun Kyoung Lee; Ok Mi Jeong; Haan Woo Sung; Jae Hong Kim; Jun Hun Kwon
Journal:  J Vet Sci       Date:  2008-03       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.